To evaluate, in the framework of translational studies, vaccine leads lost in the valley of death from the start of the SarsCovid19 pandemic to the first vaccine. Systematic review
DOI:
https://doi.org/10.56294/piii2024332Keywords:
Vaccines, Sars-Cov-2, Biomedical research, Severe acute respiratory syndrome-related coronavirus, Translational researchAbstract
Background: Translational studies and translational research refer to a process that aims to take discoveries from basic sciences to develop effective actions for the benefit of the population. These studies have different stages and in this systematic review I will focus on the valley of death or translational gap ("translational bridge") of vaccine prospects lost in this statistical space, having as a timeframe the beginning of the Covid19 pandemic, until the approval of the first vaccine. Material and methods: I will use the clinicaltrials.gov search engine to track studies from phase 1, considering that the common starting point for all studies is the discovery of a new coronavirus until phase 4. Results: Phase I the average of the JADAD Scale obtained is 3.6, Phase II 3.1 on average and Phase III 3.3. Conclusion: In these studies, other scales are used to measure methodological quality, since their inability to significantly predict the progression of vaccine leaflet studies suggests that other factors may be influencing decision making to advance to subsequent clinical phases
References
económica). Debe declararse la transparencia de la investigación.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. agosto de 2004;3(8):673-83.
Woolf SH. The Meaning of Translational Research and Why It Matters. JAMA. 9 de enero de 2008;299(2):211-3.
Fontanarosa PB, DeAngelis CD. Basic Science and Translational Research in JAMA. JAMA. 3 de abril de 2002;287(13):1728.
Ioannidis JPA. Why Most Published Research Findings Are False. PLOS Med. 30 de agosto de 2005;2(8):e124.
Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Transl Med Commun. 18 de noviembre de 2019;4(1):18.
Ioannidis JPA. Why Most Clinical Research Is Not Useful. PLOS Med. 21 de junio de 2016;13(6):e1002049.
Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy Amst Neth. abril de 2011;100(1):4-17.
Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. marzo de 2012;11(3):191-200.
Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. julio de 2015;14(7):47586.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Piero Enrico Ceroni Rossi, Eduardo Teragni (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
